Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 46 to 60 of 159 results for urinary tract infection

  1. BladderScan BVI 9400 3D portable ultrasound scanner for measuring bladder volume (MIB50)

    NICE has developed a medtech innovation briefing (MIB) on the BladderScan BVI 9400 3D portable ultrasound scanner for measuring bladder volume

    Medtech innovation briefing
    Published
    22 January 2016

  2. Memokath-028, 044 and 045 stents for urethral obstruction (MIB123)

    NICE has developed a medtech innovation briefing (MIB) on Memokath-028, 044 and 045 stents for urethral obstruction .

    Medtech innovation briefing
    Published
    2 October 2017

  3. Renal and ureteric stones (QS195)

    This quality standard covers assessing and managing renal and ureteric stones in children, young people and adults. It describes high-quality care in priority areas for improvement.

    Quality standard
    Published
    29 July 2020
    View quality statements

    Sections for QS195

  4. Rezum for treating lower urinary tract symptoms secondary to benign prostatic hyperplasia (HTG545)

    Evidence-based recommendations on Rezum for treating lower urinary tract symptoms secondary to benign prostatic hyperplasia.

    HealthTech guidance
    Published
    24 June 2020
    View recommendations

    Sections for HTG545

  5. QuickChange Incontinence Wrap for urinary incontinence in men (MIB237)

    NICE has developed a medtech innovation briefing (MIB) on QuickChange Incontinence Wrap for urinary incontinence in men .

    Medtech innovation briefing
    Published
    24 November 2020

  6. Complicated intra-abdominal infections: ceftolozane/tazobactam (ESNM75)

    Summary of the evidence on ceftolozane/tazobactam for treating complicated intra-abdominal infections to inform local NHS planning and decision-making

    Evidence summary
    Published
    9 June 2016

  7. Cryotherapy as a primary treatment for prostate cancer (HTG91)

    Evidence-based recommendations on cryotherapy as a primary treatment for prostate cancer. This involves using cold temperature to freeze and destroy cancer tissue as a first treatment for cancer that hasn't spread far from the prostate.

    HealthTech guidance
    Published
    23 November 2005
    View recommendations

    Sections for HTG91

  8. Jaundice in newborn babies under 28 days (CG98)

    This guideline covers diagnosing and treating jaundice, which is caused by increased levels of bilirubin in the blood, in newborn babies (neonates). It aims to help detect or prevent very high levels of bilirubin, which can be harmful if not treated.

    Clinical guideline
    Last updated
    31 October 2023
    View recommendations

    Sections for CG98

  9. Focal therapy using cryoablation for localised prostate cancer (HTG284)

    Evidence-based recommendations on focal therapy using cryoablation for localised stage prostate cancer. This involves using freezing (cryotherapy) needles to find and destroy only the cancerous part of the prostate.

    HealthTech guidance
    Published
    26 April 2012
    View recommendations

    Sections for HTG284

  10. Urinary incontinence and pelvic organ prolapse in women. Patient decision aid on surgery for stress urinary incontinence

    Surgery for stress urinary incontinence Patient decision aid ? 1 c NICE 2019. All rights reserved. Subject to Notice of rights. Last...

  11. Empagliflozin in combination therapy for treating type 2 diabetes (TA336)

    Evidence-based recommendations on empagliflozin (Jardiance) in combination therapy for treating type 2 diabetes.

    Technology appraisal guidance
    Published
    25 March 2015
    View recommendations

    Sections for TA336

  12. Mirabegron for treating symptoms of overactive bladder (TA290)

    Evidence-based recommendations on mirabegron (Betmiga) for treating overactive bladder in adults.

    Technology appraisal guidance
    Published
    26 June 2013
    View recommendations

    Sections for TA290

  13. Management strategies to reduce the risk of symptomatic urinary tract infections:- In people with neurogenic lower urinary tract dysfunction, which management strategies (including the use of prophylactic antibiotics and various invasive and non-invasive techniques to aid bladder drainage) reduce the risk of symptomatic urinary tract infections?

    strategies to reduce the risk of symptomatic urinary tract infections:- In people with neurogenic lower urinary...

    Research recommendation
    Published
    9 June 2015

  14. Fever in under 5s (QS64)

    This quality standard covers the assessment and early management of fever with no obvious cause in babies and children (from birth to 5 years). It describes high-quality care in priority areas for improvement.

    Quality standard
    Last updated
    27 July 2022
    View quality statements

    Sections for QS64

  15. Antimicrobial prescribing: ceftolozane with tazobactam for treating hospital-acquired pneumonia, including ventilator-associated pneumonia (ES22)

    Summary of the evidence on the antimicrobial prescribing of ceftolozane with tazobactam for hospital-acquired pneumonia, including ventilator-associated

    Evidence summary
    Published
    18 December 2019